Peptide · Fact sheet
Plecanatide
Also known as Trulance · uroguanylin analog
Plecanatide is FDA approved as Trulance for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It is not approved for general gut health, detoxification, inflammation, or tissue repair.
What is Plecanatide?
Plecanatide is a 16-amino-acid analog of uroguanylin that activates guanylate cyclase-C on the intestinal surface.
Like linaclotide, it is minimally absorbed and its evidence is tied to local bowel and abdominal-symptom outcomes.
Benefits people look for
It offers a second approved peptide approach to gut-surface guanylate cyclase-C signaling.
Comparing it with linaclotide illustrates why related mechanisms still require product-specific efficacy and safety evidence.
What the evidence supports
- Controlled trials found higher composite response rates than placebo for IBS-C and chronic idiopathic constipation.
- Benefits are averages in defined trial populations and do not imply response for every person with constipation.
All research areas
- Chronic idiopathic constipation
- IBS with constipation
- Abdominal pain and bloating
- Bowel-frequency outcomes
- Additional analyses of symptom response within the approved adult populations
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The label carries a boxed warning about serious dehydration in young pediatric patients and is not approved for pediatric use.
- Diarrhea is the most common adverse reaction and can be severe.
- It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesMultiple Phase 3 trials support the adult constipation indications. Evidence does not extend to children, unrelated digestive conditions, or broad gut-wellness claims.
Selected research to read
Controlled adult evidence for composite and individual symptom outcomes.
Subgroup analysis illustrating efficacy, safety, and limitations in older participants.
FDA approval & research status
Trulance is FDA approved for adults with chronic idiopathic constipation and adults with irritable bowel syndrome with constipation.
Approved uses covered here
- Chronic idiopathic constipation and IBS with constipation in adults under the Trulance label
FDA approved for adult constipation indications
Plecanatide is approved under the Trulance label for chronic idiopathic constipation and IBS with constipation in adults.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Long-term head-to-head effectiveness versus linaclotide and other approved options
- Reliable predictors of response and severe diarrhea
- Safety and effectiveness outside the approved adult populations
- Whether exploratory symptom composites translate into meaningful daily-life improvement
The takeaway
Plecanatide is a legitimate local gut peptide medicine for two adult constipation disorders—not a general-purpose gut or recovery peptide.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Trulance
Approved adult indications, boxed warning, contraindications, and adverse reactions.
- 2pubmedIntegrated analysis of two Phase 3 IBS-C trials
Controlled adult evidence for composite and individual symptom outcomes.
- 3pubmedPooled Phase 3 analysis in older adults
Subgroup analysis illustrating efficacy, safety, and limitations in older participants.